Liquidia Corporation (LQDA)
NASDAQ: LQDA
· Real-Time Price · USD
13.21
0.38 (2.96%)
At close: Jun 27, 2025, 11:20 AM
2.96% (1D)
| Bid | 13.2 |
| Market Cap | 1.13B |
| Revenue (ttm) | 14.14M |
| Net Income (ttm) | -127.83M |
| EPS (ttm) | -1.71 |
| PE Ratio (ttm) | -7.73 |
| Forward PE | -123.73 |
| Analyst | Buy |
| Ask | 13.22 |
| Volume | 576,382 |
| Avg. Volume (20D) | 2,134,204.7 |
| Open | 12.79 |
| Previous Close | 12.83 |
| Day's Range | 12.66 - 13.32 |
| 52-Week Range | 8.26 - 19.41 |
| Beta | 0.04 |
About LQDA
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol LQDA
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for LQDA stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
Liquidia Corporation is scheduled to release its earnings on Aug 6, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 weeks ago
-16.87%
Liquidia shares are trading lower in reaction to I...
Unlock content with
Pro Subscription
3 weeks ago
+13.07%
Liquidia shares are trading higher after the company announced it began shipping its newly FDA-approved Yutrepia. Additionally, Needham raised its price target on the stock from $25 to $32.
2 weeks ago · https://thefly.com
Liquidia price target lowered by $2 at BofA, here's whyLiquidia -2.845 (-15.80%) Insmed +19.21 (+27.19%) 17 Jun
